Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody

Prostate

Volumn 74, Issue 7, 2014, Pages 743-755

  Wiehr, Stefan ^a   Bühler, Patrick ^b   Gierschner, Dorothee ^b   Wolf, Philipp ^b   Rolle, Anna Maria ^a   Kesenheimer, Christian ^a   Pichler, Bernd J ^a   Elsässer Beile, Ursula ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

antibody; fragment; immuno PET; prostate cancer; PSMA

Indexed keywords

MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT D7 CH3 ANTIBODY; RECOMBINANT D7 FC ANTIBODY; RECOMBINANT PROSTATE SPECIFIC MEMBRANE ANTIGEN; TETRAXETAN; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; COMPARATIVE STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; KIDNEY CLEARANCE; MALE; MOUSE; NONHUMAN; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOACTIVITY; TUMOR XENOGRAFT;

ANTIBODY; FRAGMENT; IMMUNO-PET; PROSTATE CANCER; PSMA;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; TISSUE DISTRIBUTION;

EID: 84898808426     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22794     Document Type: Article

References (55)

1. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ,. Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002; 42 (1): 18-23.
2. Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R,. Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncol 2002; 41 (5): 425-429.
3. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK,. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001; 57 (1): 108-111.
4. Breeuwsma AJ, Pruim J, Jongen MM, Suurmeijer AJ, Vaalburg W, Nijman RJ, de Jong IJ,. In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 2005; 32 (6): 668-673.
5. Kukuk D, Reischl G, Raguin O, Wiehr S, Judenhofer MS, Calaminus C, Honndorf VS, Quintanilla-Martinez L, Schonberger T, Duchamp O, Machulla HJ, Pichler BJ,. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models. J Nucl Med 2011; 52 (10): 1654-1663.
6. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U,. Comparison of PET imaging with a Ga-labelled PSMA ligand and F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41 (1): 11-20. doi: 10.1007/s00259-013-2525-5. Epub 2013 Sep 27.
7. De Gaetano AM, Calcagni ML, Rufini V, Valentini AL, Gui B, Giordano A, Bonomo L,. Imaging of gynecologic malignancies with FDG PET-CT: Case examples, physiologic activity, and pitfalls. Abdom Imaging 2009; 34: 696-711.
8. Rioja J, Rodriguez-Fraile M, Lima-Favaretto R, Rincon-Mayans A, Penuelas-Sanchez I, Zudaire-Bergera JJ, Parra RO,. Role of positron emission tomography in urological oncology. BJU Int 2010; 106: 1578-1593.
9. van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR,. Immuno-PET: A navigator in monoclonal antibody development and applications. Oncologist 2007; 12 (12): 1379-1389.
10. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB,. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999; 59 (13): 3192-3198.
11. Israeli RS, Powell CT, Fair WR, Heston WD,. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53 (2): 227-230.
12. Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW,. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med 2013; 54 (8): 1369-1376.
13. Lesche R, Kettschau G, Gromov AV, Bohnke N, Borkowski S, Monning U, Hegele-Hartung C, Dohr O, Dinkelborg LM, Graham K,. Preclinical evaluation of BAY 1075553, a novel F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging 2014; 41 (1): 89-101. doi: 10.1007/s00259-013-2527-3. Epub 2013 Aug 17.
14. Eder M, Eisenhut M, Babich J, Haberkorn U,. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging 2013; 40 (6): 819-823.
15. Nelson AL, Dhimolea E, Reichert JM,. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9 (10): 767-774.
16. Horoszewicz JS, Kawinski E, Murphy GP,. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7 (5B): 927-935.
17. Haseman MK, Reed NL, Rosenthal SA,. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 1996; 21 (9): 704-713.
18. Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J,. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med 2011; 52 (10): 1608-1615.
19. Bander NH,. Technology insight: Monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 2006; 3 (4): 216-225.
20. Troyer JK, Beckett ML, Wright GL Jr., Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 1997; 30 (4): 232-242.
21. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS,. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010; 51 (8): 1293-1300.
22. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH,. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007; 25 (5): 540-547.
23. Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM,. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res 2013; 19 (18): 5182-5191.
24. Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW,. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009; 69 (17): 6932-6940.
25. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM,. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40 (4): 486-495.
26. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM,. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with 18F-FECH. Eur J Nucl Med Mol Imaging 2012; 39 (6): 1085-1086.
27. Jackson PF, Cole DC, Slusher BS, Stetz SL, Ross LE, Donzanti BA, Trainor DA,. Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem 1996; 39 (2): 619-622.
28. Frigerio B, Fracasso G, Luison E, Cingarlini S, Mortarino M, Coliva A, Seregni E, Bombardieri E, Zuccolotto G, Rosato A, Colombatti M, Canevari S, Figini M,. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. Eur J Cancer 2013; pii: S0959-8049(13)00087-7. doi: 10.1016/j.ejca.2013.01.024. [Epub ahead of print]
29. Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U,. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 2006; 66 (13): 1359-1370.
30. Elsasser-Beile U, Reischl G, Wiehr S, Buhler P, Wolf P, Alt K, Shively J, Judenhofer MS, Machulla HJ, Pichler BJ,. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009; 50 (4): 606-611.
31. Alt K, Wiehr S, Ehrlichmann W, Reischl G, Wolf P, Pichler BJ, Elsasser-Beile U, Buhler P,. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 2010; 70 (13): 1413-1421.
32. Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM,. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 2005; 65 (2): 622-631.
33. Wolf P, Alt K, Wetterauer D, Buhler P, Gierschner D, Katzenwadel A, Wetterauer U, Elsasser-Beile U,. Preclinical evaluation of a recombinant anti-prostate specific membrane antigen single-chain immunotoxin against prostate cancer. J Immunother 2010; 33 (3): 262-271.
34. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, Anderson CJ, Welch MJ,. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 1997; 24 (1): 35-43.
35. Lewis MR, Wang M, Axworthy DB, Theodore LJ, Mallet RW, Fritzberg AR, Welch MJ, Anderson CJ,. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. J Nucl Med 2003; 44 (8): 1284-1292.
36. Judenhofer MS, Wehrl HF, Newport DF, Catana C, Siegel SB, Becker M, Thielscher A, Kneilling M, Lichy MP, Eichner M, Klingel K, Reischl G, Widmaier S, Rocken M, Nutt RE, Machulla HJ, Uludag K, Cherry SR, Claussen CD, Pichler BJ,. Simultaneous PET-MRI: A new approach for functional and morphological imaging. Nat Med 2008; 14 (4): 459-465.
37. Hanahan D, Weinberg RA,. Hallmarks of cancer: The next generation. Cell 2011; 144 (5): 646-674.
38. Kenanova VE, Olafsen T, Salazar FB, Williams LE, Knowles S, Wu AM,. Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. Protein Eng Des Sel 2010; 23 (10): 789-798.
39. Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM, Sandlie I,. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem 2012; 287 (27): 22927-22937.
40. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM,. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996; 56 (13): 3055-3061.
41. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, Ober RJ, Ward ES,. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997; 15 (7): 637-640.
42. Verel I, Visser GW, van Dongen GA,. The promise of immuno-PET in radioimmunotherapy. J Nucl Med 2005; 46 (Suppl 1): 164S-171S.
43. Wu AM, Olafsen T,. Antibodies for molecular imaging of cancer. Cancer J 2008; 14 (3): 191-197.
44. Holliger P, Hudson PJ,. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23 (9): 1126-1136.
45. Jain RK,. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990; 50 (3 Suppl): 814s-819s.
46. Holliger P, Prospero T, Winter G,. " Diabodies": Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 1993; 90 (14): 6444-6448.
47. Tsai SW, Li L, Williams LE, Anderson AL, Raubitschek AA, Shively JE,. Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments. Bioconjug Chem 2001; 12 (2): 264-270.
48. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, Bair HJ, Wolf FG, Becker WS, Goldenberg DM,. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995; 55 (17): 3825-3834.
49. Girgis MD, Kenanova V, Olafsen T, McCabe KE, Wu AM, Tomlinson JS,. Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res 2011; 170 (2): 169-178.
50. Li L, Turatti F, Crow D, Bading JR, Anderson AL, Poku E, Yazaki PJ, Williams LE, Tamvakis D, Sanders P, Leong D, Raubitschek A, Hudson PJ, Colcher D, Shively JE,. Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET. J Nucl Med 2010; 51 (7): 1139-1146.
51. Eder M, Knackmuss S, Le Gall F, Reusch U, Rybin V, Little M, Haberkorn U, Mier W, Eisenhut M,. 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J Nucl Med Mol Imaging 2010; 37 (7): 1397-1407.
52. Yazaki PJ, Wu AM, Tsai SW, Williams LE, Ikler DN, Wong JY, Shively JE, Raubitschek AA,. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: Comparison to radioiodinated fragments. Bioconjug Chem 2001; 12 (2): 220-228.
53. Vaccaro C, Zhou J, Ober RJ, Ward ES,. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005; 23 (10): 1283-1288.
54. Peng F, Liu J, Wu JS, Lu X, Muzik O,. Mouse extrahepatic hepatoma detected on MicroPET using copper (II)-64 chloride uptake mediated by endogenous mouse copper transporter 1. Mol Imaging Biol 2005; 7 (5): 325-329.
55. Puig S, Thiele DJ,. Molecular mechanisms of copper uptake and distribution. Curr Opin Chem Biol 2002; 6 (2): 171-180.